Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Immunoglobulin G (IgG), typically administered as intravenous immunoglobulin (IVIG), has scientific validation as a treatment in certain cases of severe or refractory rashes and hives, particularly when these are due to immune-mediated or autoimmune etiologies. For example, IVIG is an established treatment for chronic idiopathic urticaria (hives) that does not respond to conventional therapies, as well as for severe cases associated with autoimmune diseases such as systemic lupus erythematosus or dermatomyositis. The use of IVIG in these contexts is based on its ability to modulate immune responses, neutralize pathogenic autoantibodies, and suppress inflammatory pathways. Multiple case reports, small series, and some clinical trials have demonstrated improvements in skin symptoms following IVIG administration. However, the quality and quantity of evidence supporting its routine use for all rashes and hives are limited, as many cases are self-limited or respond to antihistamines or corticosteroids. The American Academy of Allergy, Asthma, and Immunology (AAAAI) and other expert guidelines only recommend IVIG for specific, severe, or refractory situations. Therefore, while there is scientific evidence supporting the use of IgG in certain severe immune-mediated dermatologic conditions, it is not broadly indicated for all rashes or hives, and its use should be reserved for select cases where conventional therapy fails or is contraindicated.

More about immunoglobin G
More about Rashes and Hives

Other ingredients used for Rashes and Hives

Other health conditions supported by immunoglobin G

Products containing immunoglobin G